$ISO News
Last published 3y ago
- 3y agoBLIISOCELLBerkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology CompanyPR NewswirePhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its
- 3y agoATCXDCTISOMAXRMoore Kuehn Encourages ATCX, DCT, ISO, and MAXAR Investors to Contact Law FirmGlobeNewswireNEW YORK, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoAQUADCTISOMAXRMoore Kuehn Encourages AQUA, DCT, ISO, and MAXAR Investors to Contact Law FirmPR NewswireNEW YORK, Jan. 24, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
- 3y agoISOIsoPlexis Reports Preliminary Full Year 2022 RevenueGlobeNewswireBRANFORD, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary
- 3y agoBLIISOCELLBerkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology CompanyGlobeNewswireComplementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in
- 3y agoBLIISOCELLBerkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology CompanyPR NewswireComplementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in
- 4y agoISOIsoPlexis Reports Third Quarter 2022 Financial ResultsGlobeNewswireBRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results
- 4y agoISOIsoPlexis to Participate in Upcoming Investor ConferencesGlobeNewswireBRANFORD, Conn., Nov. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be
- 4y agoISOIsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022GlobeNewswireBRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report
- 4y agoISOIsoPlexis Announces First APAC Publication, Illustrating Early Impact of Codeplex PlatformGlobeNewswireBRANFORD, Conn., Sept. 13, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO) ("IsoPlexis"), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced the publication of initial data off
- 4y agoISOIsoPlexis Partners with MediMergent and The Center for Cancer and Blood Disorders in Study of AZD7442 for Prevention of COVID-19 Infection in Immuno-Compromised Cancer PatientsGlobeNewswireBRANFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- IsoPlexis (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a partnership with MediMergent, LLC, and The Center for Can
- 4y agoISOIsoPlexis to Participate in the Morgan Stanley Global Healthcare ConferenceGlobeNewswireBRANFORD, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO) ("IsoPlexis"), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the upcom
- 4y agoCCTSISOMDWDSSKNIsoPlexis Announces the Appointment of former Luminex Corporation Chairman and CEO, Nachum "Homi" Shamir to its Board of DirectorsGlobeNewswireBRANFORD, Conn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO) ("IsoPlexis"), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced the appointment of Nachum "Homi" Sham
- 4y agoISOIsoPlexis Reports Second Quarter 2022 Financial ResultsGlobeNewswireBRANFORD, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended June 30, 202
- 4y agoISOIsoPlexis to Report Second Quarter 2022 Financial Results on August 10, 2022GlobeNewswireBRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), the Superhuman Cell Company, today announced it will report financial results for the second quarter 2022 before market open on Wednesday, August 10, 2022. Company m
- 4y agoISOIsoPlexis Reports First Quarter 2022 Financial ResultsGlobeNewswireBRANFORD, Conn., May 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), the Superhuman Cell Company, today reported financial results for the quarter ended March 31, 2022. Recent Highlights Revenue of $4.9 million for the first qua
- 4y agoISOIsoPlexis Reports Preliminary First Quarter 2022 Revenue, Streamlines Operating Structure to Support Sustainable GrowthGlobeNewswireBRANFORD, Conn., April 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO) ("IsoPlexis"), the Superhuman Cell Company, today announced its preliminary unaudited revenue for the first quarter of 2022 and the transition to an integrated comme
- 4y agoISOIsoPlexis to Present First-of-Its-Kind Data on Simultaneous Single Cell TCR Profiling and Highly Multiplexed Functional Proteomics at AACR 2022GlobeNewswireBRANFORD, Conn., April 08, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), the Superhuman Cell Company, today announced that data generated using its Duomic™ platform demonstrates the ability to connect T Cell Receptor (TCR) diversity
- 4y agoISOIsoPlexis Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Revenue Outlook for 2022GlobeNewswireBRANFORD, Conn., March 02, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), the Superhuman Cell Company, today reported financial results for the quarter and year ended December 31, 2021. Recent Highlights Revenue of $5.5 million
- 4y agoISOIsoPlexis to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022GlobeNewswireBRANFORD, Conn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), the Superhuman Cell Company, today announced it will report financial results for the fourth quarter and full year 2021 before market open on Wednesday, March 2, 202
- 4y agoISOIsoPlexis to Participate in Three Upcoming Investor ConferencesGlobeNewswireBRANFORD, Conn., Feb. 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), the Superhuman Cell Company, today announced the company will be participating in the following investor conferences. 11th Annual SVB Leerink Global Healthcare C
- 4y agoISOIsoPlexis' Immune Monitoring Helps Identify Early Factors of Long COVID in Cell PublicationGlobeNewswireBRANFORD, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), the Superhuman Cell Company, today announced the publication of a study in Cell, led by the Institute for Systems Biology and Seattle COVID consortium, in which re
- 4y agoISOIsoPlexis Strengthens International Reach and Leadership with First APAC Office and Jason Ou as President/General Manager, APAC RegionGlobeNewswireBRANFORD, Conn., Feb. 02, 2022 (GLOBE NEWSWIRE) -- IsoPlexis, the Superhuman Cell Company, today announced the opening of its first office in the Asia-Pacific (APAC) region headed by Jason Ou as President/General Manager, APAC Region. In this role, Mr.
- 4y agoISOIsoPlexis Reports Preliminary Full Year 2021 Revenue, Releases Industry-First Superhuman Cell LibraryGlobeNewswireBRANFORD, Conn., Jan. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis (NASDAQ: ISO), the Superhuman Cell Company, today announced its preliminary unaudited revenue for the full year 2021. Total revenue for 2021 is expected to be in the range of $17.0 to $17.2
- 4y agoISOIsoPlexis to Present IsoLight® Single-Cell Proteomics Data at ASH 2021 ConferencePR NewswireBRANFORD, Conn., Dec. 8, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single cell proteomics, today announced that new data generated on its IsoLight® platform will be presented at the 63rd annual American Society of Hematolo
- 4y agoISOIsoPlexis Appoints Key Financial and Legal Hires from Leading Tools and Omics CompaniesPR NewswireBRANFORD, Conn., Nov. 30, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of Richard Rew as Senior VP, General Counsel and Secretary; Raj Khakhar as VP of Finance; and Mann
- 4y agoISOIsoPlexis to Participate in the Evercore ISI HealthCONx ConferencePR NewswireBRANFORD, Conn., Nov. 24, 2021 /PRNewswire/ -- IsoPlexis Corporation (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the company will be participating virtually in the upcoming Evercore ISI 4th Annual HealthCONx Conference
- 4y agoISOIsoPlexis' Expanded Cell Therapy Offerings Demonstrated in Nature Medicine PublicationsPR NewswireBRANFORD, Conn., Nov. 18, 2021 /PRNewswire/ -- IsoPlexis Corporation (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the publication of two high-impact clinical research studies in Nature Medicine. Both papers demonstrate
- 5y agoISOIsoPlexis Bolsters Its Global Operational and Product Support LeadershipPR NewswireBRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service
- 5y agoISOIsoPlexis Reports Third Quarter 2021 Financial ResultsPR NewswireBRANFORD, Conn., Nov. 10, 2021 /PRNewswire/ -- IsoPlexis Corporation (NASDAQ:ISO), the leader in functional single-cell proteomics, today reported financial results for the quarter ended September 30, 2021.
- 5y agoISOIsoPlexis to Present Data at SITC 2021 Connecting Genetic Drivers to Functional ProteomicsPR NewswireBRANFORD, Conn., Nov. 5, 2021 /PRNewswire/ -- IsoPlexis Corporation (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced that data generated on its IsoLight® and IsoSpark® Platforms will be presented at the 35th Annual Meet
- 5y agoISOIsoPlexis to Report Third Quarter Financial Results on November 10, 2021PR NewswireBRANFORD, Conn., Oct. 26, 2021 /PRNewswire/ -- IsoPlexis Corporation (NASDAQ:ISO), a leader in functional single-cell proteomics, today announced it will report financial results for the third quarter 2021 before market open on Wednesday, November 10, 2
- 5y agoISOIsoPlexis Announces Closing of Public OfferingPR NewswireBRANFORD, Conn., Oct. 12, 2021 /PRNewswire/ -- IsoPlexis Corporation ("IsoPlexis"), a leader in functional single-cell proteomics, today announced the closing of its initial public offering of 8,333,000 shares of common stock at a public offering price
- 5y agoISOIsoPlexis Announces Pricing of Initial Public OfferingPR NewswireBRANFORD, Conn., Oct. 7, 2021 /PRNewswire/ -- IsoPlexis Corporation ("IsoPlexis"), a leader in functional single-cell proteomics, today announced the pricing of its initial public offering of 8,333,000 shares of common stock at a public offering price